

Information for Connecticut Prescribers of Prescription Drugs

Zepbound® (tirzepatide) injection

- Connecticut Public Act No. 23-171 requires “pharmaceutical representatives” (as defined in the Act) to provide certain information to prescribers and pharmacists. The information in this disclosure is being provided pursuant to this Act.
- Lilly USA LLC's Wholesale Acquisition Cost (WAC) is the listed price to the distribution channel not including prompt pay, service or administrative fees, stocking or distribution allowances, or any discounts, rebates, or chargebacks provided by Lilly USA to any entity.
- Lilly USA LLC's direct to patient price is the price at which Lilly sells the product directly to patients. The direct to patient price is not the WAC, as the product is only available for purchase by cash paying patients.

Product:

| BRAND NAME | GENERIC NAME | STRENGTH | DOSAGE FORM | PACK SIZE | NDC | WHOLESALE ACQUISITION COST ¹ |
|------------|-----------------------|----------------|-------------------------------------|-----------|--------------|---|
| Zepbound® | tirzepatide injection | 2.5 mg/0.5 mL | Single-Dose Pen | 4 | 0002-2506-80 | \$1086.37 |
| | | 5 mg/0.5 mL | Single-Dose Pen | 4 | 0002-2495-80 | \$1086.37 |
| | | 7.5 mg/0.5 mL | Single-Dose Pen | 4 | 0002-2484-80 | \$1086.37 |
| | | 10 mg/0.5 mL | Single-Dose Pen | 4 | 0002-2471-80 | \$1086.37 |
| | | 12.5 mg/0.5 mL | Single-Dose Pen | 4 | 0002-2460-80 | \$1086.37 |
| | | 15 mg/0.5 mL | Single-Dose Pen | 4 | 0002-2457-80 | \$1086.37 |
| | | 2.5 mg/0.6 mL | Single-Patient-Use KwikPen®, 2.4 mL | 1 | 0002-3566-11 | \$499.00 |
| | | 5 mg/0.6 mL | Single-Patient-Use KwikPen, 2.4 mL | 1 | 0002-3555-11 | \$499.00 |
| | | 7.5 mg/0.6 mL | Single-Patient-Use KwikPen, 2.4 mL | 1 | 0002-3544-11 | \$499.00 |
| | | 10 mg/0.6 mL | Single-Patient-Use KwikPen, 2.4 mL | 1 | 0002-3533-11 | \$699.00 |
| | | 12.5 mg/0.6 mL | Single-Patient-Use KwikPen, 2.4 mL | 1 | 0002-3522-11 | \$699.00 |
| | | 15 mg/0.6 mL | Single-Patient-Use KwikPen, 2.4 mL | 1 | 0002-3511-11 | \$699.00 |

| BRAND NAME | GENERIC NAME | STRENGTH | DOSAGE FORM | PACK SIZE | NDC | DIRECT TO PATIENT PRICE ¹ |
|------------|-----------------------|----------------|------------------|-----------|--------------|--------------------------------------|
| Zepbound® | tirzepatide injection | 2.5 mg/0.5 mL | Single-Dose Vial | 4 | 0002-0152-04 | \$299.00 |
| | | 5 mg/0.5 mL | Single-Dose Vial | 4 | 0002-0243-04 | \$399.00 |
| | | 7.5 mg/0.5 mL | Single-Dose Vial | 4 | 0002-1214-04 | \$499.00 |
| | | 10 mg/0.5 mL | Single-Dose Vial | 4 | 0002-1340-04 | \$699.00 |
| | | 12.5 mg/0.5 mL | Single-Dose Vial | 4 | 0002-1423-04 | \$699.00 |
| | | 15 mg/0.5 mL | Single-Dose Vial | 4 | 0002-2002-04 | \$699.00 |

In adult patients with obesity or overweight, a reduction in body weight was observed with ZEPBOUND® irrespective of race or ethnicity.²

See [Prescribing Information](#), including Boxed Warnings.

Zepbound®, its delivery device base, and KwikPen® are registered trademarks owned or licensed by Eli Lilly and Company, its subsidiaries, or affiliates.

¹ Source: AnalySource®. Accessed on 02/24/2026. WAC reprinted with permission by First Databank Inc. All rights reserved. © 2026. <http://www.fdbhealth.com/policies/drug-pricing-policy/>.

² US Zepbound Prescribing Information.